180 Life Sciences Stock (NASDAQ:ATNF)


RevenueOwnershipFinancialsChart

Previous Close

$3.74

52W Range

$1.16 - $17.75

50D Avg

$2.45

200D Avg

$2.46

Market Cap

$3.51M

Avg Vol (3M)

$2.00M

Beta

0.45

Div Yield

-

ATNF Company Profile


1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

4

IPO Date

Jun 27, 2017

Website

ATNF Performance


ATNF Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-13.48T$-17.90M$-15.64M
Net Income$-19.94T$-38.73M$-20.32M
EBITDA$-13.48T$-17.79M$-14.76M
Basic EPS$-52.59$-20.38$-12.96
Diluted EPS$-52.59$-20.38$-12.96

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
ZVSAZyVersa Therapeutics, Inc.
CNSPCNS Pharmaceuticals, Inc.
PHIOPhio Pharmaceuticals Corp.
EFTReFFECTOR Therapeutics, Inc.
IMMXImmix Biopharma, Inc.
CYTOAltamira Therapeutics Ltd.
SONNSonnet BioTherapeutics Holdings, Inc.
ZURAZura Bio Limited
CDIOCardio Diagnostics Holdings, Inc.
ENVBEnveric Biosciences, Inc.
PALIPalisade Bio, Inc.